Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

The trial will assess if the drug may be able to prevent infection among patients who have been exposed and treat those who have been infected with the disease.

Regeneron Antibody Therapy For Covid-19 Enters Late-Stage Trials

Regeneron stock neared a buy point Monday as the drugmaker announced it started late-stage tests on a coronavirus treatment in conjunction with federal health officials.

Regeneron Nears Buy Point As Drugmaker Begins Late-Stage Covid-19 Tests

DexCom

PayPal

Find out who's winning out among hundreds of companies.

The 3 Best S&P 500 Stocks So Far in 2020

Shares of Regeneron Pharmaceuticals Inc. REGN, +2.18% gained 4.6% in premarket trading on Monday after the drugmaker said it had begun a Phase 3 clinical trial testing an antibody cocktail to prevent COVID-19.

Regeneron shares gain as the company launches Phase 3 trial for COVID-19 antibody treatment

Regeneron Pharmaceuticals said on Monday it began late-stage clinical trials to assess the effectiveness of its antibody cocktail in preventing and treating Covid-19.

Regeneron begins coronavirus antibody cocktail late-stage trial

TARRYTOWN, N.Y., July 6, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the initiation of late-stage clinical trials evaluating REGN-COV2, Regeneron's investigational double antibody cocktail for the treatment and prevention of COVID-19. A Phase 3...

Regeneron Announces Start of REGN-COV2 Phase 3 COVID-19 Prevention Trial in Collaboration with National Institute of Allergy and Infectious Diseases (NIAID)

Emergent BioSolutions

Both of these companies could play a huge role in ending the COVID-19 pandemic.

Better Coronavirus Stock: Emergent Biosolutions vs. Regeneron

Exelixis

Genmab - ADR

Vertex Pharmaceuticals

These five biotech stocks have already gone on heaters of 30% or more in 2020, and all of them still have plenty of upside to spare.

5 Booming Biotech Stocks to Buy

Sanofi

Sanofi (SNY) and Regeneron discontinue U.S.-based phase III coronavirus study on Kevzara following failure to achieve improvement in hospitalized patients with severe COVID-19 patients of statistical significance.

Sanofi/Regeneron's Kevzara Fails in Phase III Coronavirus Study

AstraZeneca

Gritstone Oncology Inc

iShares Nasdaq Biotechnology ETF

Novavax

For the most part, biotech and pharmaceutical companies are involved in the lengthy process of getting their drug candidates to market through clinical trials.

5 FDA COVID-19 Decisions in July Could Make or Break Stocks

Kevzara failed to help the most severely affected COVID-19 patients.

Regeneron's Arthritis Drug Fails COVID-19 Trial

SAN FRANCISCO, July 2, 2020 /PRNewswire/ -- Hagens Berman urges longtime shareholders in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) to submit their losses now. The firm is investigating whether Regeneron's directors breached their fiduciary duties. Relevant Holding Period: At least...

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Longtime Shareholders in Regeneron Pharmaceuticals (REGN) to Contact its Attorneys: Firm Investigating Possible Breach of Fiduciary Duties

Shares of Regeneron Pharmaceuticals Inc. REGN, +2.18% were down 2.4% and Sanofi's SNY, +0.68% stock declined 1.7% in after-hours trading on Friday after the companies halted a Phase 3 clinical trial testing their rheumatoid arthritis drug Kevzara as a COVID-19 treatment.

Regeneron, Sanofi halt trial for experimental coronavirus drug, shares fall

TARRYTOWN, N.Y. and PARIS, July 2, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Phase 3 trial of Kevzara® (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary...

Regeneron and Sanofi Provide Update on Kevzara® (sarilumab) Phase 3 U.S. Trial in COVID-19 Patients

Apple

Adobe

Etsy

Fastly

Lululemon Athletica

Netflix

NVIDIA

Shopify

Tesla

Twilio

Wix.com

Zoom Video

The best stocks of the second quarter were the ones with "a lot of ingenuity and a lot more good luck," the "Mad Money" host said.

Jim Cramer breaks down his favorite stocks from a record second quarter

Speaking at a high school graduation in Yorktown, NY, Regeneron cofounder and Chief Scientific Officer Dr. George Yancopoulos said that police are “scapegoats” for larger race issues.

Regeneron’s Billionaire Cofounder Criticized After ‘All Lives Matter’ Graduation Speech

Why There Is Still Time For A Long In Regeneron

Gilead Sciences

iShares Genomics Immunology and Healthcare ETF

iShares Cybersecurity and Tech ETF

iShares Robotics & Artificial Intelligence Multisector ETF

Moderna

In this episode of ETF Spotlight, I speak with Jeff Spiegel, U.S. Head of Megatrends and International ETFs at BlackRock, about megatrend investing.

Invest in the Future With Megatrend ETFs

Alpha Pro Tech

CVS Health

Labcorp Holdings Inc

OPKO Health

I have previously discussed my views of the coronavirus pandemic, which included the fact that many states opened too early and that greater testing was needed.

The New Normal Of The Coronavirus Pandemic: Investment Implications

TARRYTOWN, N.Y., June 24, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today stated there is no merit to the civil complaint filed by the U.S. Attorney for the District of Massachusetts. It is unfortunate that a misguided lawsuit is attempting to assign wrongful...

Regeneron to Vigorously Defend Allegations Related to Contributions to a Patient Assistance Charity in 2013 and Early 2014

The U.S. Justice Department on Wednesday sued Regeneron Pharmaceuticals Inc , accusing it of using a charity that helps cover Medicare patients' drug costs as a means to pay kickbacks for using its expensive macular degeneration drug Eylea.

U.S. claims Regeneron paid kickbacks via charity to boost expensive drug

Regeneron Pharmaceuticals (REGN) Presents At BMO 2020 Prescriptions for Success Healthcare Conference Transcript

Credit Suisse

Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Credit Suisse Biotech Management & Board Call Series Conference (Transcript)

Charter Communications

PC Connection

Empire State Realty Trust

Meredith

Despite the low numbers shown in the Existing Home Sales data the went out today, June is expected to be an improvement with the economy reopened and people comfortable with seeing houses. All optimism aside, our deep learning algorithms have used AI to help you spot the Top Buys today.

Top Stocks To Buy Now As Existing Home Sales Decline In May

Regeneron (REGN) wins FDA approval for a 300-mg, single-dose, pre-filled pen for asthma drug, Dupixent.

News for Regeneron Pharmaceuticals Stock (REGN)